IGF::OT::IGF: SBIR PHASE II, TOPIC 326: DEVELOPMENT OF NOVEL THERAPEUTIC AGENTS THAT TARGET CANCER STEM CELLS

IGF::OT::IGF：SBIR 第二阶段，主题 326：开发针对癌症干细胞的新型治疗药物

• 批准号: 9361095
• 负责人: DAVID EAVARONE
• 金额: $ 149.94万
• 依托单位: SIAMAB THERAPEUTICS, INC.
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-09-19 至 2018-09-18
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9361095
• 关键词: Antibody-drug conjugates; Antigens; Cancer Relapse; Carbohydrates; Cell surface; Cellular Structures; Data; Development; Disease remission; Generations; Goals; Malignant Neoplasms; Modeling; Monoclonal Antibodies; Patients; Phase; Population; Production; Resistance; Safety; Small Business Innovation Research Grant; Therapeutic; Therapeutic Agents; Therapeutic Monoclonal Antibodies; Tissues; Toxicology; cancer cell; cancer stem cell; cell type; clinically relevant; cross reactivity; cytotoxic; in vivo; killings; novel strategies; novel therapeutics; stable cell line; tumor; tumor xenograft

Within a tumor there are two main cell types: mature cancer cells comprising the majority of a tumor and a small population of especially lethal “cancer stem cell (CSCs) resistant to treatment that can cause cancer relapse. Thus, novel strategies are needed to target and kill not only the majority of mature cancer cells but also the CSCs in order to achieve long-­‐term remissions and potential cures. Toward this end, Siamab Therapeutics, Inc. has devised a unique approach to target both mature and CSC components of a tumor using a single therapeutic monoclonal antibody (mAb) that targets a cancer-­‐associated cell-­‐surface carbohydrate antigen.

在肿瘤内有两种主要的细胞类型：成熟的癌细胞占肿瘤的大多数，以及一小部分特别致命的“癌症干细胞”(CSCs)对可能导致癌症复发的治疗具有抵抗力。因此，需要新的策略来靶向和杀死大多数成熟的癌细胞，而且还需要针对和杀死CSCs，以实现长期缓解和潜在的治愈。为此，Siamab Treateutics，Inc.设计了一种独特的方法，使用单一的治疗性单抗(MAb)来靶向肿瘤的成熟和CSC成分，该单抗 靶标是癌症相关细胞表面碳水化合物抗原。